Mitsubishi Pharma Launches Selective Antithrombin Agent Argatroban in Germany.Tokyo, Japan, July 21, 2005 - (JCNN JCNN Japan Corporate News Network ) - Mitsubishi Pharma Mitsubishi Pharma Corporation (三菱ウェルファーマ株式会社 (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4509) announced July 20 that its overseas subsidiary Mitsubishi Pharma Europe of London received approval to market argatroban, Mitsubishi Pharma's proprietary selective antithrombin agent, as of June 1 and put it on sale on July 15. Mitsubishi Pharma Deutaschland is now marketing the agent under the trade name of Argatra in Germany. Mitsubishi Pharma Europe plans to introduce the drug in Sweden, Holland, Austria, and Italy upon approval by authorities in respective countries. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion